Hanyu Pharmaceutical announced that the clinical trial application submitted by the company HY3003 injection to the US FDA was accepted on October 5, 2026, with the IND number IND 184763. According to FDA regulations, if there is no request to suspend clinical trials within 30 days from the date of acceptance by the IND, the company can conduct clinical trials in humans.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.